



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Qiulai Kou,
kouquai@163.com

[†]These authors have contributed equally
to this work and share first authorship

SPECIALTY SECTION

This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 19 October 2022
ACCEPTED 20 October 2022
PUBLISHED 03 November 2022

CITATION

Wan Y, Yang J, Ma T, Wang W, Wang H,
Sun W, Ye W, Yang L and Kou Q (2022),
Corrigendum: A Chinese medicine
formula (kunbixiao granule) for female
rheumatoid arthritis: Study protocol for
a double-blind, randomized, placebo-
controlled trial.
Front. Pharmacol. 13:1074679.
doi: 10.3389/fphar.2022.1074679

COPYRIGHT

© 2022 Wan, Yang, Ma, Wang, Wang,
Sun, Ye, Yang and Kou. This is an open-
access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial

Yingying Wan^{1†}, Jiayi Yang^{2†}, Tianyue Ma², Wenqian Wang²,
Haonan Wang¹, Wenting Sun¹, Wanting Ye², Lin Yang¹ and
Qiulai Kou^{1*}

¹Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China, ²Beijing University of Chinese Medicine, Beijing, China

KEYWORDS

rheumatoid arthritis, female, randomized controlled trial, double-blind, placebo, Chinese medicine, protocol

A Corrigendum on:

[A Chinese medicine formula \(kunbixiao granule\) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial](#)

by Wan Y, Yang J, Ma T, Wang W, Wang H, Sun W, Ye W, Yang L and Kou Q (2022). *Front Pharmacol.* 13: 945565. doi: 10.3389/fphar.2022.945565

In the published article, Jianxun Ren was erroneously included. The corrected author list and correspondence information appear below. Additionally, the Author contributions section has been revised to reflect this amendment.

Yingying Wan^{1†}, Jiayi Yang^{2†}, Tianyue Ma², Wenqian Wang², Haonan Wang¹,
Wenting Sun¹, Wanting Ye², Lin Yang¹ and Qiulai Kou^{1*}

Correspondence: Qiulai Kou, kouquai@163.com

Author Contributions: QK, YW, and JY contributed to the study design. YW drafted the manuscript, and prepared the additional files. JY was responsible for obtaining ethics approval. TM, WW, HW, WY, and WS devised and discussed the study design. LY analyzed the main components of the Chinese medicine. All authors have read and agreed with the final manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.